Skip to main content

Table 2 High levels of Annexin-A2 (ANXA2) in serum as a potential biomarker for cancers

From: Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

Tumor type N p value Results Reference
Hepatocellular carcinoma 70 <  0.001 Patients (n = 50, median, 69.6 ng/ml)
Healthy individuals (n = 20, median, 9.5 ng/ml)
[25]
Hepatocellular carcinoma (early stage) 70 <  0.01 Patients (n = 50, median, 130 ng/ml)
Healthy individuals (n = 20, median, 17 ng/ml)
[26]
Gastric cancer 93 <  0.001 Patients (n = 63, median, 211.0 ng/ml)
Healthy individuals (n = 30, median, 120.5 ng/ml)
[27]
Lung cancer 85 <  0.01 Patients (n = 42)
Healthy individuals (n = 43)
[28]
Oral squamous cell carcinoma 284 <  0.01 Patients (n = 126, median, 27.1 ng/ml)
Healthy individuals (n = 158, median, 15 ng/ml)
[29]
  1. Method: enzyme-linked immunosorbent assay; N, total number of patients